Mangrove Partners IM LLC Buys Shares of 6,317 Abbott Laboratories $ABT

Mangrove Partners IM LLC purchased a new position in Abbott Laboratories (NYSE:ABT) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 6,317 shares of the healthcare product maker’s stock, valued at approximately $846,000.

A number of other hedge funds have also made changes to their positions in ABT. Charles Schwab Trust Co boosted its holdings in shares of Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after buying an additional 15,394 shares during the period. Asset Management One Co. Ltd. lifted its position in Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after acquiring an additional 19,966 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Abbott Laboratories by 6.1% during the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares during the period. AE Wealth Management LLC grew its position in shares of Abbott Laboratories by 20.8% in the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after purchasing an additional 11,264 shares during the last quarter. Finally, Mawer Investment Management Ltd. lifted its position in shares of Abbott Laboratories by 5.9% during the 3rd quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after purchasing an additional 70,122 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last ninety days. Company insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ABT shares. Barclays lowered their target price on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Sanford C. Bernstein reduced their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Citigroup decreased their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Oppenheimer dropped their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $107.99 on Friday. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The firm’s 50 day moving average is $114.58 and its 200-day moving average is $123.91. The firm has a market capitalization of $187.66 billion, a price-to-earnings ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter last year, the business posted $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is presently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.